Ultragenyx Pharmaceutical Inc. Common Stock (RARE)

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatm…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1,371

Website

www.ultragenyx.com/

Fundamentals

1-day range

$25.45$26.73

Market cap

$2.46B

P/E (trailing)

—

P/E (forward)

38.48

EPS (trailing)

$-5.84

Dividend yield

—

Beta

0.28

Avg. volume

2.35M

Forecasts

19 analyst ratings

Ultragenyx Pharmaceutical Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RARE

  Ultragenyx Pharmaceutical Inc. Common Stock

  $25.62

  ▼ 2.46%
  Market cap $2.46BP/E —
  $18.29$39.89
• TRVI

  Trevi Therapeutics Inc. Common Stock

  $16.78

  ▼ 6.60%
  Market cap $2.54BP/E —
  $6.93$20.22
• NKTR

  Nektar Therapeutics Common Stock

  $72.57

  ▼ 2.66%
  Market cap $2.38BP/E —
  $27.87$109
• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.36BP/E —
  $2.99$7.72
• IMNM

  Immunome Inc. Common Stock

  $27.57

  ▼ 4.50%
  Market cap $2.61BP/E —
  $8.67$30.06
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.31BP/E —
  $21.2$56.05
• SUPN

  Supernus Pharmaceuticals Inc. Common Stock

  $43.76

  ▼ 0.97%
  Market cap $2.67BP/E —
  $42.45$59.68

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50
  benzinga · 8/28/2026
• Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade)
  SeekingAlpha · 8/21/2026
• Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74
  Benzinga · 8/21/2026
• Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83
  Benzinga · 8/20/2026
• Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58
  Benzinga · 8/20/2026
• Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46
  Benzinga · 8/20/2026
• Ultragenyx Nabs FDA Nod for First Gene Therapy
  Benzinga · 8/20/2026
• Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
  Benzinga · 8/20/2026
• Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript
  SeekingAlpha · 8/20/2026

• Karah Herdman Parschauer · August 3, 2026 · Sale

  1.9K @ $24.92
• Howard Horn · August 3, 2026 · Sale

  4.7K @ $24.92
• Howard Horn · July 1, 2026 · Sale

  4.7K @ $33.13
• Corazon (Corsee) D. Sanders · June 15, 2026 · Sale

  2.0K @ $25.05
• Karah Herdman Parschauer · June 15, 2026 · Sale

  1.9K @ $24.62
• Howard Horn · June 1, 2026 · Sale

  4.7K @ $23.77
• Shehnaaz Suliman · May 18, 2026 · Sale

  5.7K @ $25.12
• Amrit Ray · May 14, 2026 · Grant

  14.1K
• Amrit Ray · May 14, 2026 · Grant

  7.8K
• Corazon (Corsee) D. Sanders · May 14, 2026 · Grant

  14.1K
• Corazon (Corsee) D. Sanders · May 14, 2026 · Grant

  7.8K
• Shehnaaz Suliman · May 14, 2026 · Grant

  14.1K
• Shehnaaz Suliman · May 14, 2026 · Grant

  7.8K
• Matthew K. Fust · May 14, 2026 · Grant

  14.1K
• Matthew K. Fust · May 14, 2026 · Grant

  7.8K

Institutional Ownership

March 31, 2026

Total shares held

93.77M

Total value held

$1.87B

Institutional holders

286